MX337477B - Derivados de diaminopiridina y procesos para su preparacion. - Google Patents
Derivados de diaminopiridina y procesos para su preparacion.Info
- Publication number
- MX337477B MX337477B MX2013009549A MX2013009549A MX337477B MX 337477 B MX337477 B MX 337477B MX 2013009549 A MX2013009549 A MX 2013009549A MX 2013009549 A MX2013009549 A MX 2013009549A MX 337477 B MX337477 B MX 337477B
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- pharmaceutically acceptable
- acceptable salt
- processes
- diaminopyrimidine derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona un derivado de diaminopirimidina o su sal farmacéutica aceptable, un proceso para su preparación, una composición farmacéutica que lo comprende y el uso de los mismos. El derivado de diaminopirimidina o su sal farmacéutica aceptable funciona como un receptor 5-HT4 y por tanto puede aplicarse en forma útil para evitar o tratar disfunción en movilidad gastrointestinal, una de las enfermedades gastrointestinales, tales como enfermedad de reflujo gastroesofágico (GERD), constipación, síndrome de intestino irritable (lBS), dispepsia, íleo post-operativo, vaciado gástrico retrasado, gastroparesis, pseudo-obstrucción intestinal, tránsito retrasado inducido por fármaco, o atonía gástrica diabética.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110016981 | 2011-02-25 | ||
| PCT/KR2012/001427 WO2012115480A2 (en) | 2011-02-25 | 2012-02-24 | Diaminopyrimidine derivatives and processes for the preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013009549A MX2013009549A (es) | 2013-09-06 |
| MX337477B true MX337477B (es) | 2016-03-07 |
Family
ID=46721361
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013009627A MX336155B (es) | 2011-02-25 | 2012-02-24 | Derivados de diaminopirimidina y procesos para su preparacion. |
| MX2013009549A MX337477B (es) | 2011-02-25 | 2012-02-24 | Derivados de diaminopiridina y procesos para su preparacion. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013009627A MX336155B (es) | 2011-02-25 | 2012-02-24 | Derivados de diaminopirimidina y procesos para su preparacion. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9890138B2 (es) |
| EP (2) | EP2678332B1 (es) |
| JP (2) | JP5890436B2 (es) |
| KR (2) | KR101671341B1 (es) |
| CN (2) | CN103391935B (es) |
| AU (2) | AU2012221927B2 (es) |
| BR (2) | BR112013019942B1 (es) |
| CA (2) | CA2827072C (es) |
| DK (1) | DK2678332T3 (es) |
| ES (2) | ES2579830T3 (es) |
| HK (2) | HK1188215A1 (es) |
| HU (1) | HUE029988T2 (es) |
| IN (1) | IN2013MN01519A (es) |
| MX (2) | MX336155B (es) |
| PL (2) | PL2678332T3 (es) |
| PT (1) | PT2678332T (es) |
| RU (1) | RU2587493C2 (es) |
| WO (2) | WO2012115480A2 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2678332B1 (en) * | 2011-02-25 | 2016-05-18 | Yuhan Corporation | Diaminopyrimidine derivatives and processes for the preparation thereof |
| SG10201600149VA (en) | 2012-11-21 | 2016-02-26 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| KR101657616B1 (ko) * | 2013-05-24 | 2016-09-19 | 주식회사유한양행 | 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법 |
| EP3039015B1 (en) | 2013-08-30 | 2019-10-30 | PTC Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
| CN104003944B (zh) * | 2014-05-29 | 2016-08-24 | 西北师范大学 | 一种嘧菌胺的制备方法 |
| BR112017007769B1 (pt) * | 2014-10-13 | 2023-10-10 | Yuhan Corporation | Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos |
| US10300155B2 (en) | 2015-12-31 | 2019-05-28 | Washington University | Alpha-synuclein ligands |
| CN105646321A (zh) * | 2016-01-07 | 2016-06-08 | 中国药科大学 | (s)-3-羟基吡咯烷盐酸盐的制备方法 |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| KR102441327B1 (ko) * | 2018-05-18 | 2022-09-07 | 주식회사유한양행 | 다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법 |
| BR112021002630A2 (pt) | 2018-08-17 | 2021-05-11 | Ptc Therapeutics, Inc. | método para tratar câncer pancreático |
| CA3122182A1 (en) * | 2018-12-18 | 2020-06-25 | Astrazeneca Ab | Pharmaceutical process and intermediates |
| CN110317176A (zh) * | 2019-07-04 | 2019-10-11 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
| KR20220006776A (ko) * | 2020-07-09 | 2022-01-18 | 주식회사유한양행 | 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962115A (en) | 1981-10-01 | 1990-10-09 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| SK279058B6 (sk) | 1986-04-30 | 1998-06-03 | Dainippon Pharmaceutical Co. | Substituovaný n-[(2-morfolynyl)alkyl]banzamidový d |
| GB9005014D0 (en) | 1990-03-06 | 1990-05-02 | Janssen Pharmaceutica Nv | N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives |
| HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| WO1995010506A1 (en) * | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| EP0723533A1 (en) * | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| IL112024A (en) | 1993-12-21 | 1999-07-14 | Novo Nordisk As | Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders |
| CA2197298C (en) | 1994-08-13 | 1999-10-19 | Jong Wook Lee | Novel pyrimidine derivatives and processes for the preparation thereof |
| US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| IN188411B (es) * | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| CN100441228C (zh) * | 2003-07-25 | 2008-12-10 | 西巴特殊化学制品控股公司 | 取代的2,4-双(烷基氨基)嘧啶或-喹唑啉作为抗菌剂的用途 |
| AU2004268641A1 (en) * | 2003-08-29 | 2005-03-10 | Dynogen Pharmaceuticals, Inc. | Compositions useful for treating gastrointestinal motility disorders |
| US20060057972A1 (en) | 2004-09-14 | 2006-03-16 | Wikel Harold L | Adapter for a modular wireless communication device |
| US20060128726A1 (en) | 2004-11-24 | 2006-06-15 | Xuebao Wang | Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations |
| JP4970290B2 (ja) * | 2005-02-25 | 2012-07-04 | ファイザー株式会社 | ベンズイソキサゾール誘導体 |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| US20080293942A1 (en) * | 2005-11-28 | 2008-11-27 | Cousins Russell D | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives |
| US8044068B2 (en) * | 2006-04-04 | 2011-10-25 | Taisho Pharmaceutical Co., Ltd | Aminopyrrolidine compound |
| CA2648170A1 (en) * | 2006-04-10 | 2007-10-18 | Boehringer Ingelheim International Gmbh | 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer |
| JP5263151B2 (ja) * | 2007-03-19 | 2013-08-14 | 富士通株式会社 | データ処理装置、そのデータ監視方法、そのデータ監視プログラム、及びそのデータ監視プログラムを格納した記録媒体 |
| MX2010008700A (es) * | 2008-02-22 | 2010-08-30 | Hoffmann La Roche | Moduladores de beta-amiloide. |
| ES2659725T3 (es) * | 2009-05-05 | 2018-03-19 | Dana-Farber Cancer Institute, Inc. | Inhibidores de EGFR y procedimiento de tratamiento de trastornos |
| EP2678332B1 (en) * | 2011-02-25 | 2016-05-18 | Yuhan Corporation | Diaminopyrimidine derivatives and processes for the preparation thereof |
-
2012
- 2012-02-24 EP EP12750114.6A patent/EP2678332B1/en active Active
- 2012-02-24 KR KR1020120018926A patent/KR101671341B1/ko active IP Right Grant
- 2012-02-24 WO PCT/KR2012/001427 patent/WO2012115480A2/en active Application Filing
- 2012-02-24 US US14/001,489 patent/US9890138B2/en active Active
- 2012-02-24 BR BR112013019942-3A patent/BR112013019942B1/pt active IP Right Grant
- 2012-02-24 CN CN201280010354.3A patent/CN103391935B/zh active Active
- 2012-02-24 KR KR1020120018933A patent/KR101671348B1/ko active IP Right Grant
- 2012-02-24 CA CA2827072A patent/CA2827072C/en active Active
- 2012-02-24 BR BR112013020641-1A patent/BR112013020641B1/pt active IP Right Grant
- 2012-02-24 JP JP2013555369A patent/JP5890436B2/ja active Active
- 2012-02-24 RU RU2013142187/04A patent/RU2587493C2/ru active
- 2012-02-24 DK DK12750114.6T patent/DK2678332T3/en active
- 2012-02-24 AU AU2012221927A patent/AU2012221927B2/en active Active
- 2012-02-24 US US14/001,475 patent/US9850227B2/en active Active
- 2012-02-24 IN IN1519MUN2013 patent/IN2013MN01519A/en unknown
- 2012-02-24 HU HUE12750114A patent/HUE029988T2/en unknown
- 2012-02-24 PL PL12750114.6T patent/PL2678332T3/pl unknown
- 2012-02-24 AU AU2012221925A patent/AU2012221925B2/en active Active
- 2012-02-24 ES ES12749916.8T patent/ES2579830T3/es active Active
- 2012-02-24 CN CN201280010406.7A patent/CN103402997B/zh active Active
- 2012-02-24 WO PCT/KR2012/001423 patent/WO2012115478A2/en active Application Filing
- 2012-02-24 CA CA2827030A patent/CA2827030C/en active Active
- 2012-02-24 MX MX2013009627A patent/MX336155B/es unknown
- 2012-02-24 ES ES12750114.6T patent/ES2587304T3/es active Active
- 2012-02-24 EP EP12749916.8A patent/EP2678331B1/en active Active
- 2012-02-24 MX MX2013009549A patent/MX337477B/es active IP Right Grant
- 2012-02-24 JP JP2013555368A patent/JP5980236B2/ja active Active
- 2012-02-24 PL PL12749916.8T patent/PL2678331T3/pl unknown
- 2012-02-24 PT PT127501146T patent/PT2678332T/pt unknown
-
2014
- 2014-02-12 HK HK14101293.6A patent/HK1188215A1/xx unknown
- 2014-02-12 HK HK14101278.5A patent/HK1188214A1/zh unknown
-
2017
- 2017-11-15 US US15/813,741 patent/US10640490B2/en active Active
- 2017-12-20 US US15/848,760 patent/US10227330B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX337477B (es) | Derivados de diaminopiridina y procesos para su preparacion. | |
| WO2012115479A3 (en) | Diaminopyrimidine derivatives and processes for the preparation thereof | |
| EP3781571C0 (en) | DERIVATIVES OF N-[4-OXO-2,3-DIHYDRO-PYRIDO[3,2-B][1,4]OXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B ]PYRAZOLE-2-CARBOXAMIDE AND SIMILAR COMPOUNDS AS RIP1 KINASE INHIBITORS FOR P.E. TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS) | |
| HUP0600810A3 (en) | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them | |
| WO2008021849A3 (en) | Novel compounds as antagonists or inverse agonists at opioid receptors | |
| CL2007002499A1 (es) | Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes. | |
| EA201290254A1 (ru) | Антагонисты il-17a | |
| WO2010040508A8 (en) | Bispecific anti-vegf/anti-ang-2 antibodies | |
| WO2006104826A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| WO2007050802A3 (en) | Novel opioid antagonists | |
| WO2010123930A3 (en) | Chemosensory receptor ligand-based therapies | |
| MX2010008375A (es) | Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3). | |
| EA200600323A1 (ru) | γd-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ | |
| EA201190319A1 (ru) | Твердая фармацевтическая композиция, содержащая ривароксабан | |
| IL195514A (en) | Converted Pyridyl Compounds | |
| PL2084543T3 (pl) | Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II | |
| HUP0600809A2 (en) | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them | |
| UA100877C2 (ru) | Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3) | |
| WO2010001257A3 (en) | Novel solid state forms of laquinimod and its sodium salt | |
| WO2011045232A3 (en) | Neuropeptide-2 receptor (y-2r) agonists | |
| WO2010052144A3 (en) | Neuropeptide-2-receptor (y-2r) agonists and uses thereof | |
| EA201370219A1 (ru) | Противогипертоническая фармацевтическая композиция | |
| WO2012017448A3 (en) | Salts of lapatinib | |
| UA112764C2 (uk) | Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок | |
| IL210214A (en) | A process for preparing converted pyrimidine annals and such new compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |